NP / PA
Philips, Kezia
Philips, Kezia was paid $539K by Medicaid between Aug 2020 and Dec 2024, across 13 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 65% of everything it billed.
33Billing provider infoPHILIPS, KEZIA
ADDISON, IL 60101
ADDISON, IL 60101
33aNPI1659854198assigned 09/11/2018
33bProvider typeFamily Nurse Practitioner
28Total paid$539K
24GClaims8,917
24DCodes billed13
24AFirst – last monthAug 2020 – Dec 2024
Compared with peers
Next to other Family Nurse Practitioner providers in Illinois
Rank by total paid#62 of 3,353
Median peer was paid$25K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 447 | $28K | |
| 2021 | 1,343 | $76K | |
| 2022 | 2,615 | $161K | |
| 2023 | 2,655 | $146K | |
| 2024incomplete | 1,857 | $127K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 65% | 4,412 | 3,086 | $348K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 1,887 | 1,473 | $96K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.8% | 568 | 531 | $26K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 3.7% | 486 | 439 | $20K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.3% | 485 | 453 | $13K |
| 93000 | 2.1% | 560 | 525 | $12K | |
| 94010 | 2.1% | 307 | 281 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 95 | 88 | $5K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 44 | 29 | $4K |
| 95924 | <1% | 21 | 13 | $2K | |
| 95923 | <1% | 21 | 13 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 17 | 16 | $1K |
1 more codes
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 14 | $328.44 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.